cyclophosphamide + docetaxel + endostatin + epirubicin

This is a combination chemotherapy regimen consisting of four agents: - **Cyclophosphamide** (an alkylating agent that crosslinks DNA, leading to cell death) - **Docetaxel** (a taxane that stabilizes microtubules and inhibits cell division) - **Endostatin** (an endogenous angiogenesis inhibitor that blocks the formation of new blood vessels required for tumor growth) - **Epirubicin** (an anthracycline antibiotic that intercalates into DNA and inhibits topoisomerase II, causing DNA damage and apoptosis) This multi-agent regimen is designed to target cancer cells through multiple mechanisms—direct cytotoxicity, inhibition of mitosis, antiangiogenic effects, and interference with DNA replication. While combinations such as docetaxel plus cyclophosphamide or epirubicin plus cyclophosphamide are established in breast cancer treatment[1][2][3], the addition of endostatin represents an investigational approach aimed at enhancing anti-tumor efficacy by also targeting tumor vasculature. The primary indications for these drugs individually or in dual/triple combinations include various solid tumors such as breast cancer; however, this specific four-drug combination is not a standard protocol but may be explored in clinical trials.